Unlock Healing: Stem Cell Therapy in the United States
This advanced regenerative protocol is specifically designed to support patients with Congestive Heart Failure (CHF) by improving cardiac function, reducing inflammation, and enhancing myocardial repair. The treatment utilizes Mesenchymal Stem Cells (MSCs) derived from either Adipose tissue or Umbilical Cord Cells, depending on patient suitability and desired potency. These MSCs possess strong anti-inflammatory and angiogenic properties that promote new blood vessel formation, reduce scar tissue, and improve heart muscle contractility.
The therapy is further enhanced with Exosomes, the bioactive vesicles naturally secreted by stem cells that deliver growth factors and genetic material directly to damaged cardiac cells. Exosomes amplify the regenerative signals of MSCs, improving cellular communication and accelerating the repair of weakened heart tissue while reducing oxidative stress.
To optimize healing and cardiovascular performance, the protocol includes the peptides BPC-157 and TB-500. BPC-157 supports endothelial repair, improves microcirculation, and reduces vascular inflammation, while TB-500 enhances cardiac cell regeneration, elasticity, and oxygen delivery to the myocardium.
The treatment is administered via Intravenous infusion, with an optional targeted intramyocardial or intra-arterial injection to enhance delivery to the cardiac region.
Goal: Strengthen cardiac function, improve circulation, reduce inflammation, and promote long-term myocardial regeneration for improved quality of life and endurance.
Share this listing